Hospital
Baptist Healthcare System, INC.
Baptist Healthcare System, INC. was paid $16.01M by Medicaid between Jan 2018 and Dec 2024, across 196 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoBAPTIST HEALTHCARE SYSTEM, INC.
LA GRANGE, KY 40031
LA GRANGE, KY 40031
33aNPI1306925540assigned 11/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$16.01M
24GClaims452,910
24DCodes billed196
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#27 of 36
Median peer was paid$36.08M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CARRICO, RICHARD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 60,662 | $1.63M | |
| 2019 | 57,822 | $1.67M | |
| 2020 | 58,552 | $1.86M | |
| 2021 | 69,446 | $2.43M | |
| 2022 | 77,584 | $3.64M | |
| 2023 | 72,205 | $2.58M | |
| 2024incomplete | 56,639 | $2.21M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 18,564 | 16,433 | $2.71M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 10.0% | 7,533 | 3,288 | $1.60M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.0% | 6,525 | 5,498 | $1.43M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.9% | 3,198 | 2,769 | $943K |
| J9271 | Injection, pembrolizumab, 1 mg | 5.8% | 150 | 86 | $927K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.3% | 5,616 | 2,772 | $523K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.8% | 9,490 | 5,836 | $442K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.6% | 14,993 | 5,300 | $416K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.6% | 1,559 | 1,249 | $410K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.5% | 4,017 | 3,699 | $404K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.4% | 1,433 | 1,293 | $377K |
| G0378 | Hospital observation service, per hour | 2.0% | 957 | 791 | $317K |
184 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 2,372 | $304K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 54,043 | $255K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.5% | 3,147 | $240K |
| 80053 | Comprehensive metabolic panel | 1.4% | 33,806 | $229K |
| 36415 | Collection of venous blood by venipuncture | 1.4% | 58,112 | $221K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 624 | $210K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.3% | 6,699 | $209K |
| 96367 | 1.3% | 3,633 | $205K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 10,103 | $200K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.2% | 2,236 | $199K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 3,401 | $176K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 468 | $175K |
| 59025 | Fetal non-stress test | 1.0% | 2,039 | $162K |
| 76641 | <1% | 1,466 | $152K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,251 | $130K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,106 | $106K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 265 | $97K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,770 | $96K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,795 | $91K |
| 76642 | <1% | 1,164 | $83K | |
| 19083 | <1% | 108 | $83K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,010 | $75K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,482 | $69K |
| 77066 | Tomosynthesis, mammo | <1% | 973 | $68K |
| 73630 | <1% | 1,012 | $60K | |
| 80306 | <1% | 3,803 | $58K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,757 | $55K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,327 | $48K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 311 | $48K |
| 96415 | <1% | 361 | $45K | |
| 96376 | <1% | 1,417 | $45K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 928 | $43K |
| 77065 | Tomosynthesis, mammo | <1% | 752 | $42K |
| 82728 | <1% | 3,470 | $40K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 542 | $39K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 685 | $38K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 2,283 | $38K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,033 | $36K |
| 73610 | <1% | 587 | $35K | |
| 97161 | <1% | 1,014 | $34K | |
| 84484 | <1% | 4,392 | $34K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,911 | $29K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 501 | $29K |
| 84466 | <1% | 2,538 | $27K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,847 | $27K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,729 | $26K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 389 | $24K |
| J0897 | Injection, denosumab, 1 mg | <1% | 16 | $23K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 74 | $22K |
| 96417 | <1% | 209 | $22K | |
| 83880 | <1% | 743 | $21K | |
| 36591 | <1% | 1,698 | $20K | |
| 96402 | <1% | 82 | $20K | |
| 83735 | <1% | 3,094 | $19K | |
| 83690 | <1% | 4,394 | $19K | |
| 81001 | <1% | 8,686 | $19K | |
| 73130 | <1% | 295 | $18K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,960 | $18K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,746 | $17K |
| 83540 | <1% | 3,154 | $17K | |
| 84703 | <1% | 3,177 | $17K | |
| 96411 | <1% | 78 | $16K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,264 | $15K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 91 | $14K |
| 0002A | <1% | 454 | $14K | |
| 73562 | <1% | 238 | $14K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,834 | $14K |
| 0001A | <1% | 505 | $13K | |
| 81025 | <1% | 3,052 | $13K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 235 | $12K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,284 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 467 | $12K |
| 80061 | Lipid panel | <1% | 1,219 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 421 | $11K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,109 | $11K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 294 | $11K |
| 85610 | <1% | 3,542 | $11K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,577 | $11K |
| 73030 | <1% | 219 | $11K | |
| 85027 | <1% | 2,015 | $10K | |
| 74018 | <1% | 183 | $10K | |
| 87081 | <1% | 1,996 | $10K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 89 | $9K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 12 | $9K |
| 71250 | <1% | 87 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,392 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 661 | $8K |
| 85379 | <1% | 1,059 | $7K | |
| 81003 | <1% | 4,029 | $7K | |
| 72100 | <1% | 180 | $7K | |
| 84145 | <1% | 381 | $7K | |
| 83605 | <1% | 957 | $6K | |
| 82962 | <1% | 2,440 | $6K | |
| 82077 | <1% | 523 | $6K | |
| 96523 | <1% | 395 | $6K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,061 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 137 | $6K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 32 | $6K |
| 77080 | <1% | 150 | $5K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,353 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 27 | $5K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,935 | $5K |
| J3490 | Unclassified drugs | <1% | 65 | $5K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 13 | $5K |
| 85730 | <1% | 1,338 | $5K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 614 | $5K |
| 84100 | <1% | 894 | $5K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,737 | $5K |
| 84439 | <1% | 599 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,579 | $4K |
| 0100U | <1% | 50 | $4K | |
| 87040 | <1% | 635 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,136 | $4K |
| 86850 | <1% | 480 | $3K | |
| 93971 | <1% | 27 | $3K | |
| 82607 | <1% | 240 | $3K | |
| 82948 | <1% | 566 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,271 | $3K |
| 84702 | <1% | 302 | $3K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 796 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 157 | $2K |
| 85046 | <1% | 575 | $2K | |
| 73110 | <1% | 60 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 6,832 | $2K |
| 86901 | <1% | 858 | $2K | |
| 86900 | <1% | 872 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 353 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 130 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,277 | $2K |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 12 | $2K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 110 | $2K |
| 83615 | <1% | 290 | $1K | |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 20 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,065 | $1K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 45 | $1K |
| 96368 | <1% | 19 | $1K | |
| 87807 | <1% | 153 | $1K | |
| 84112 | <1% | 14 | $1K | |
| 80050 | General health panel | <1% | 31 | $1K |
| 0071A | <1% | 27 | $922.52 | |
| 90715 | <1% | 42 | $921.35 | |
| 71271 | <1% | 15 | $839.30 | |
| 73502 | <1% | 12 | $836.21 | |
| 71101 | <1% | 12 | $789.12 | |
| 36416 | <1% | 470 | $779.20 | |
| 0072A | <1% | 23 | $744.48 | |
| 72072 | <1% | 13 | $725.21 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 277 | $721.65 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 660 | $703.81 |
| 87186 | <1% | 138 | $703.06 | |
| 72040 | <1% | 17 | $681.51 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 75 | $662.22 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 173 | $615.39 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 15 | $595.21 |
| 82746 | <1% | 49 | $562.25 | |
| 94761 | <1% | 100 | $530.76 | |
| 82784 | <1% | 30 | $489.51 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 106 | $457.72 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 89 | $436.84 |
| 88304 | <1% | 29 | $429.26 | |
| 83550 | <1% | 58 | $397.14 | |
| 87070 | <1% | 42 | $155.11 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 89 | $150.82 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 27 | $130.25 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 300 | $128.72 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 30 | $115.80 |
| 85652 | <1% | 46 | $114.45 | |
| 87210 | <1% | 57 | $98.07 | |
| 82550 | <1% | 19 | $97.65 | |
| 87147 | <1% | 18 | $96.32 | |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 31 | $90.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 122 | $75.32 |
| 82570 | <1% | 18 | $67.34 | |
| 86140 | <1% | 19 | $59.26 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 20 | $46.56 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 38 | $46.29 |
| 84132 | <1% | 19 | $46.07 | |
| 81002 | <1% | 16 | $43.80 | |
| G0306 | Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count | <1% | 2,069 | $37.68 |
| 87220 | <1% | 14 | $28.64 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 14 | $2.73 |
| 99499 | 0% | 13 | $0.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 227 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARRICO, RICHARD (CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.